Genprex Inc (GNPX) Stock Price, Quote & News

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 774 4679

Website: www.genprex.com

Address:

3300 Bee Cave Road, Suite 650-227, Austin, United States

zannnn May. 22 at 2:33 PM

$GNPX

0 · Reply

TwongStocks May. 21 at 9:22 PM

$GNPX ASCO Abstract Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmi. https://www.asco.org/abstracts-presentations/264606 Conclusions: Following up on preclinical cell line and organoid models indicating that Trop-2 and PTEN protein expression correlated with response, levels of Trop-2 and PTEN protein were evaluated in patients treated with quaratusugene ozeplasmid. Despite the small number of samples evaluated, both Trop-2 H-scores above 100 and PTEN H-scores below 100 correlated with longer PFS in patients with NSCLC, but not in patients with SCLC.

0 · Reply

TwongStocks May. 21 at 8:40 PM

$GNPX The ASCO abstract will be public at 5:00pm ET. Direct link to abstract 👇👇

0 · Reply

P_etheris May. 21 at 8:26 AM

$GNPX Firstly, I am not shorting this (that is pretty much just HC Wainwright) Secondly, my average is not anymore over $1 Thirdly, I can read the chart and I see what will happen. And I remember you stupid nickname and stupid ideas which were constantly wrong, mostly on tickers which were absolute SCAMS🤷🏻‍♂️ You have a 🧠 like a bird …but you might be good looking 😉

0 · Reply

LastDODO May. 21 at 8:16 AM

$GNPX just a reminder of the play this dude is in... eating both sides great. Hate against dodo's not too good. Good luck going short while holding an average over a dollar 👍🏼

0 · Reply

zannnn May. 20 at 11:05 PM

$GNPX

0 · Reply

Jsubsierra May. 20 at 9:58 PM

$GNPX +500%

0 · Reply

P_etheris May. 20 at 7:23 PM

$GNPX I’ve seen this tard at BINI and Romeo Power 🤣🤣🤣 (check what happened with that companies…) With his investing ideas, I would be very surprised if he has still money left to invest …or pay his bill for internet 🤣🤦🏻‍♂️

0 · Reply

LastDODO May. 20 at 6:51 PM

$GNPX this is why I am still invested here. For diabetic people all over the globe this could be life changing. Quote from last 8K: "The Company believes that its therapy holds the potential to offer long-term glycemic control, moving beyond symptomatic management to fundamentally address the disease for diabetic patients."

0 · Reply

ka1954 May. 20 at 2:27 PM

$GNPX why the fuck this company doesn't hire traders to run up the stock 500%+ like other biotech stocks to do their fucking dilution? they could do this so easily

0 · Reply

Genprex collaborators present positive preclinical data of GPX-002 in diabetes

May 14, 2026, 8:00 AM EDT - 8 days ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

2026-04-30T17:03:52.000Z - 22 days ago

Genprex receives patent grant from The Israel Patent Office

Apr 30, 2026, 8:00 AM EDT - 22 days ago

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Apr 28, 2026, 7:00 AM EDT - 24 days ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Apr 22, 2026, 7:00 AM EDT - 4 weeks ago

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

2026-04-21T11:09:56.000Z - 4 weeks ago

Genprex enters research agreement with UT MD Anderson

Apr 21, 2026, 7:00 AM EDT - 4 weeks ago

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

2026-04-20T11:26:41.000Z - 4 weeks ago

Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR

Apr 20, 2026, 7:00 AM EDT - 4 weeks ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

2026-03-18T11:11:22.000Z - 2 months ago

Genprex collaborators present on use of Reqorsa at AACR meeting

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Genprex to Participate at BIO Europe Spring 2026

2026-02-23T13:12:47.000Z - 3 months ago

Genprex granted Japanese and EU patents for Reqorsa Gene Therapy

Feb 23, 2026, 8:00 AM EST - 3 months ago

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

2026-02-10T13:05:58.000Z - 3 months ago

Genprex’s patent application for Reqorsa Gene Therapy accepted by IP Australia

Feb 10, 2026, 8:00 AM EST - 3 months ago

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Jan 7, 2026, 7:00 AM EST - 4 months ago

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

2026-01-06T12:05:20.000Z - 4 months ago

Genprex reports ‘positive’ preclinical data from study of GPX-002

Jan 6, 2026, 7:00 AM EST - 4 months ago

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

2025-11-24T12:10:18.000Z - 6 months ago

Genprex publishes data from Acclaim-1 Phase 1 trial of Reqorsa Gene Therapy

Nov 24, 2025, 7:00 AM EST - 6 months ago

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

2025-11-21T22:00:33.000Z - 6 months ago

Genprex files to sell 1.28M shares of common stock for holders

2025-11-19T12:10:46.000Z - 6 months ago

Genprex adds Gabrail Cancer Center for Acclaim clinical trials 1 and 3

AZN

Nov 19, 2025, 7:00 AM EST - 6 months ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

2025-11-18T12:21:46.000Z - 6 months ago

Genprex granted U.S. patenet for Reqorsa Gene Therapy in cancer

Nov 18, 2025, 7:00 AM EST - 6 months ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

2025-11-04T12:50:41.000Z - 7 months ago

Genprex on path to receive European patent for Reqorsa in cancer

Nov 4, 2025, 7:00 AM EST - 7 months ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

2025-10-28T15:30:20.000Z - 7 months ago

Genprex trading resumes

2025-10-28T15:25:18.000Z - 7 months ago

Genprex trading halted, volatility trading pause

2025-10-28T15:25:12.000Z - 7 months ago

Genprex announces registered direct offering of up to $10M

Oct 28, 2025, 11:19 AM EDT - 7 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

2025-10-28T11:11:48.000Z - 7 months ago

Genprex presents positive preclinical data on Reqorsa Gene Therapy

Oct 28, 2025, 7:00 AM EDT - 7 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-23T12:15:23.000Z - 7 months ago

Genprex announces $8.1M registered direct offering priced at-the-market

Oct 23, 2025, 8:12 AM EDT - 7 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 7:00 AM EDT - 7 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-20T23:50:17.000Z - 7 months ago

Genprex trading halted, news pending

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Aug 18, 2025, 9:29 AM EDT - 9 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 4, 2025, 8:30 AM EDT - 10 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Jun 24, 2025, 9:25 AM EDT - 11 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 11 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Genprex to Participate at BIO 2025 International Convention

May 29, 2025, 7:00 AM EDT - 1 year ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 28, 2025, 7:00 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 7, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 6, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 22, 2025, 8:15 AM EDT - 1 year ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 25, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 4, 2025, 8:15 AM EST - 1 year ago

Genprex to Participate at BIO Europe Spring 2025

Feb 19, 2025, 8:15 AM EST - 1 year ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 18, 2025, 8:15 AM EST - 1 year ago

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 13, 2025, 8:15 AM EST - 1 year ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

zannnn May. 22 at 2:33 PM

$GNPX

0 · Reply

TwongStocks May. 21 at 9:22 PM

0 · Reply

TwongStocks May. 21 at 8:40 PM

$GNPX The ASCO abstract will be public at 5:00pm ET. Direct link to abstract 👇👇

0 · Reply

P_etheris May. 21 at 8:26 AM

0 · Reply

LastDODO May. 21 at 8:16 AM

$GNPX just a reminder of the play this dude is in... eating both sides great. Hate against dodo's not too good. Good luck going short while holding an average over a dollar 👍🏼

0 · Reply

zannnn May. 20 at 11:05 PM

$GNPX

0 · Reply

Jsubsierra May. 20 at 9:58 PM

$GNPX +500%

0 · Reply

P_etheris May. 20 at 7:23 PM

0 · Reply

LastDODO May. 20 at 6:51 PM

0 · Reply

ka1954 May. 20 at 2:27 PM

$GNPX why the fuck this company doesn't hire traders to run up the stock 500%+ like other biotech stocks to do their fucking dilution? they could do this so easily

0 · Reply

MrAlientrader May. 20 at 2:03 PM

$GNPX don’t think dilution make any sense, stock down 20% four days with just total trading volume around 600k shares

0 · Reply

uptrend2025 May. 20 at 1:57 PM

$GNPX This one has still ways to go down because of the ATM usage reported in the Q

1 · Reply

ka1954 May. 20 at 1:53 PM

$GNPX with this low daily volume. its just retail idiots selling at loss or short selling the stock

0 · Reply

zannnn May. 20 at 9:27 AM

$GNPX

0 · Reply

P_etheris May. 20 at 7:05 AM

$GNPX ☝️🤣🤣🤣 Today? Tmrw? This week? I feel it, it is close 😉

0 · Reply

AimHighnuwillhitsomewer May. 19 at 3:19 PM

$GNPX Now Dilution. Wait for .30. Then a small pump. r/s after. Last but not least an offering even u before you BLINK. CEO is filling up his coffers from retail. Already 3 r/s took place. Thats the pattern. S O R R Y

0 · Reply

ka1954 May. 19 at 1:47 PM

$GNPX 2-3% down everyday. what the fuck is wrong this fucking stock ?

1 · Reply

Swing22 May. 19 at 12:52 PM

$GNPX these guys still killing it huh

0 · Reply

P_etheris May. 19 at 12:32 PM

$GNPX This Balkan disco boy is retarded 🤣🤣🤣⏬️ No message… just “bullish” 🤦🏻‍♂️ He is bullish from like $9 🤣🤣🤣 Seriously, he is like broken kitchen blender 🤖 Watch this move to 75c TODAY☝️

0 · Reply

zannnn May. 19 at 11:08 AM

$GNPX

1 · Reply

MB76 May. 19 at 1:51 AM

$GNPX This guy is absolute SCUM!!!!!!!!!!

0 · Reply

MB76 May. 19 at 1:49 AM

$GNPX Are the resident SCUM pumpers still here?

0 · Reply

Market Cap	8.36M
Revenue (ttm)	0.00
Net Income (ttm)	-16.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	236,800
Avg Vol	713,600
Day's Range	N/A - N/A
Shares Out	10.59M
Stochastic %K	54%
Beta	-0.94
Analysts	Strong Buy
Price Target	$7.50